新闻通稿

/新闻通稿

Oramed to Present at BIO International Convention

NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business Development of Oramed, will deliver a corporate presentation, including an [...]

2019-06-03T09:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at ThinkEquity Conference

NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. [...]

2019-04-29T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at 3rd Annual Clinical Trials Summit

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]

2019-04-11T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Patent Allowed in the U.S. for Oral Exenatide

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]

2019-04-04T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at H.C. Wainwright Global Life Sciences Conference

NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place [...]

2019-04-03T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for [...]

2019-03-28T08:40:00+00:00 Categories: 新闻通稿|Tags: |

Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed’s Oral Insulin Capsules

NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of [...]

2019-03-26T08:40:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]

2019-02-06T08:25:00+00:00 Categories: 新闻通稿|Tags: |